Program Description and Objectives
Patients with end-stage liver disease commonly develop AKI. Within the spectrum of AKI, the most severe form associated with liver disease is the hepatorenal syndrome. In recent years, a greater understanding of the pathophysiology of this disorder has led to potential therapeutic options. This symposium focuses on the pathophysiology of the hepatorenal syndrome, the kidney manifestations of liver disease, and the therapeutic options for addressing this condition.

Upon completion of this symposium, the participant will be able to: 1) describe the major pathophysiological mechanisms involved in the development of the hepatorenal syndrome; 2) distinguish the various forms of AKI that are associated with advanced liver disease; and 3) review therapeutic options for the treatment of the hepatorenal syndrome.

Target Audience
Physicians
Researchers
Medical and Other Trainees—including medical students, residents, graduate students, and post-docs

Nurses and Nurse Practitioners
Pharmacists
Physician Assistants
Other health care professional

Faculty
Robert Schrier
Patrick Northup
Andrew Davenport
Florence Wong